Transcode Therapeutics, INC 8-K filings

TransCode Therapeutics' Safety Review Committee has approved the opening of the third cohort in its Phase 1 clinical trial for TTX-MC138, following positive safety data from the second cohort and promising preliminary results from the first cohort.

TransCode Therapeutics has successfully entered into a securities purchase agreement for a private placement expected to yield approximately $8 million in gross proceeds.

TransCode Therapeutics has implemented a 1-for-33 reverse stock split to increase its share price and maintain its listing on the Nasdaq Capital Market.

TransCode Therapeutics' stockholders approved the ratification of a share issuance and a reverse stock split at a special meeting held on November 22, 2024.

TransCode Therapeutics has received an extension from Nasdaq to regain compliance with listing rules after a shareholder approval issue related to a share issuance.

TransCode Therapeutics is facing potential delisting from the Nasdaq Capital Market due to deficiencies in minimum bid price, stockholders' equity, and shareholder approval for a recent stock offering.

TransCode Therapeutics is at risk of being delisted from the Nasdaq Capital Market due to failing to meet minimum share price and stockholders' equity requirements.

TransCode Therapeutics has received notices from Nasdaq regarding deficiencies in its minimum bid price and stockholders' equity, potentially leading to delisting.

TransCode Therapeutics has entered into an agreement to sell 10 million shares of its common stock at $0.30 per share in a public offering, expected to close on July 24, 2024.

TransCode Therapeutics filed an amendment to its original 8-K report to correct the voting results of its annual meeting, revealing that the reverse stock split proposal was not approved by shareholders.

TransCode Therapeutics held its annual meeting on June 13, 2024, where directors were elected, a stock plan amendment was approved, and a reverse stock split proposal was rejected.

TransCode Therapeutics has regained compliance with Nasdaq's minimum bid price requirement, leading to the cancellation of a scheduled hearing.

TransCode Therapeutics has received a stay on its delisting from the Nasdaq Capital Market pending a hearing scheduled for June 25, 2024, to appeal the delisting determination.

TransCode Therapeutics, Inc. is appealing a delisting notice from Nasdaq due to its failure to meet the minimum bid price requirement and stockholders' equity requirement.

TransCode Therapeutics has announced its 2024 annual meeting date as June 13, 2024, and established deadlines for shareholder proposals and director nominations.

TransCode Therapeutics announced its 2023 financial results, highlighted by advancing its lead therapeutic candidate, TTX-MC138, into a Phase 1 clinical trial and securing over $25 million in equity financing.

TransCode Therapeutics has regained compliance with Nasdaq's minimum stockholders' equity requirement but will be subject to a one-year monitoring period.

TransCode Therapeutics successfully closed a public offering, raising $7.25 million to advance its RNA therapeutic programs.

TransCode Therapeutics has announced a 1-for-40 reverse stock split and the resignation of its CEO, effective January 13, 2024.